CA3053675A1 - Anti-vegf antibody - Google Patents

Anti-vegf antibody Download PDF

Info

Publication number
CA3053675A1
CA3053675A1 CA3053675A CA3053675A CA3053675A1 CA 3053675 A1 CA3053675 A1 CA 3053675A1 CA 3053675 A CA3053675 A CA 3053675A CA 3053675 A CA3053675 A CA 3053675A CA 3053675 A1 CA3053675 A1 CA 3053675A1
Authority
CA
Canada
Prior art keywords
antibody
amino acid
antibodies
vegf
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3053675A
Other languages
English (en)
French (fr)
Inventor
Yaohuang Ke
Weimin Zhu
Guo-Liang Yu
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Publication of CA3053675A1 publication Critical patent/CA3053675A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3053675A 2008-03-26 2008-10-08 Anti-vegf antibody Abandoned CA3053675A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039719 2008-03-26
CA2981887A CA2981887C (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2981887A Division CA2981887C (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Publications (1)

Publication Number Publication Date
CA3053675A1 true CA3053675A1 (en) 2009-10-01

Family

ID=41114205

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3053675A Abandoned CA3053675A1 (en) 2008-03-26 2008-10-08 Anti-vegf antibody
CA2719400A Active CA2719400C (en) 2008-03-26 2008-10-08 Anti-vegf antibody
CA2981887A Active CA2981887C (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2719400A Active CA2719400C (en) 2008-03-26 2008-10-08 Anti-vegf antibody
CA2981887A Active CA2981887C (en) 2008-03-26 2008-10-08 Anti-vegf antibody

Country Status (9)

Country Link
US (2) US7803371B2 (https=)
EP (1) EP2259795B1 (https=)
JP (2) JP5823858B2 (https=)
KR (1) KR101581244B1 (https=)
CN (2) CN102065888B (https=)
AU (1) AU2008353479B2 (https=)
BR (1) BRPI0822556B1 (https=)
CA (3) CA3053675A1 (https=)
WO (1) WO2009120178A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
CN103087192B (zh) * 2011-11-02 2015-02-04 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
WO2015103139A1 (en) * 2013-12-31 2015-07-09 Development Center For Biotechnology Anti-vegf antibodies and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3244738A4 (en) * 2015-01-16 2018-12-05 Alder Biopharmaceuticals, Inc. Anti-glycoprotein antibodies and uses thereof
US10344081B2 (en) * 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3154214A1 (en) * 2019-09-13 2021-03-18 adMare Therapeutics Society Anti-oncolytic virus antigen antibodies and methods of using same
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4642805A4 (en) * 2022-12-29 2026-04-22 Ltz Therapeutics Inc Anti-cd79b antibodies and uses thereof
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2004016740A2 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
AU2003259718A1 (en) * 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Also Published As

Publication number Publication date
AU2008353479A1 (en) 2009-10-01
CA2981887A1 (en) 2009-10-01
EP2259795A4 (en) 2012-06-06
CA2981887C (en) 2019-09-03
CA2719400A1 (en) 2009-10-01
HK1201280A1 (en) 2015-08-28
WO2009120178A1 (en) 2009-10-01
BRPI0822556A2 (pt) 2020-08-18
JP5823858B2 (ja) 2015-11-25
JP2014205674A (ja) 2014-10-30
KR20100132983A (ko) 2010-12-20
CN102065888A (zh) 2011-05-18
CA2719400C (en) 2017-11-14
JP2011517447A (ja) 2011-06-09
US20110008367A1 (en) 2011-01-13
AU2008353479B2 (en) 2014-02-20
US20090246190A1 (en) 2009-10-01
CN102065888B (zh) 2014-03-26
CN103992405B (zh) 2016-08-17
US7803371B2 (en) 2010-09-28
US8088375B2 (en) 2012-01-03
EP2259795B1 (en) 2016-04-06
EP2259795A1 (en) 2010-12-15
KR101581244B1 (ko) 2015-12-31
BRPI0822556B1 (pt) 2022-03-03
CN103992405A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
CA2719400C (en) Anti-vegf antibody
JP5738294B2 (ja) 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物
US7431927B2 (en) TNFα-neutralizing antibodies
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
US20050282233A1 (en) Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
JP2011525360A (ja) 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
US20250129177A1 (en) Combination Therapy Involving Anti-CD39 Antibodies and Anti-PD-1 or Anti-PD-L1 Antibodies
CN116209676A (zh) Lair-1结合剂及其使用方法
KR20220119117A (ko) 종양 특이적 claudin 18.2 항체
TW202339799A (zh) 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
AU2014202474B2 (en) Anti-VEGF antibody
HK1201280B (en) Anti-vegf antibody
JP6568557B2 (ja) 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
WO2026044246A1 (en) Anti-cadherin-17 antibodies and use thereof
WO2025214468A1 (zh) 抗il-15抗体以及其用途
HK40048531B (zh) 抗pd-l1/抗4-1bb双特异性抗体及其用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831